Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial

• Published in: Scientific reports 2022-01, Vol.12 (1), p.1346-11, Article 1346
• Main Authors: Kellar, Derek, Register, Thomas, Lockhart, Samuel N., Aisen, Paul, Raman, Rema, Rissman, Robert A., Brewer, James, Craft, Suzanne
• Format: Article
• Language: English
• Subjects: 631/250; 631/378; 692/308; 692/53; 692/617; 692/699; Administration, Intranasal; Aged; Alzheimer Disease - drug therapy; Alzheimer's disease; Biomarkers - cerebrospinal fluid; CCL22 protein; Cerebrospinal fluid; Clinical trials; Cognition & reasoning; Cognitive ability; Cohort Studies; Cytokines; Eotaxin; Female; Humanities and Social Sciences; Humans; Immune response; Inflammation; Inflammation - drug therapy; Insulin; Insulin - pharmacology; Interleukin 2; Interleukin 6; Male; Middle Aged; multidisciplinary; Neurodegenerative diseases; Placebos; Science; Science (multidisciplinary); Tau protein; γ-Interferon
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-05165-3

Intranasal insulin (INI) has shown promise as a treatment for Alzheimer’s disease (AD) in pilot clinical trials. In a recent phase 2 trial, participants with mild cognitive impairment (MCI) or AD who were treated with INI with one of two delivery devices showed improved cerebral spinal fluid (CSF) biomarker profiles and slower symptom progression compared with placebo. In the cohort which showed benefit, we measured changes in CSF markers of inflammation, immune function and vascular integrity and assessed their relationship with changes in cognition, brain volume, and CSF amyloid and tau concentrations. The insulin-treated group had increased CSF interferon-γ (p = 0.032) and eotaxin (p = 0.049), and reduced interleukin-6 (p = 0.048) over the 12 month trial compared to placebo. Trends were observed for increased CSF macrophage-derived chemokine for the placebo group (p = 0.083), and increased interleukin-2 in the insulin-treated group (p = 0.093). Insulin-treated and placebo groups showed strikingly different patterns of associations between changes in CSF immune/inflammatory/vascular markers and changes in cognition, brain volume, and amyloid and tau concentrations. In summary, INI treatment altered the typical progression of markers of inflammation and immune function seen in AD, suggesting that INI may promote a compensatory immune response associated with therapeutic benefit.